Notably, MIC-1 alone can achieve 38.5% (79/205) positive detection rate in early-stage CRC patients (stage I and II) whereas CEA can only detect 27.3% early-stage patients, suggesting that MIC-1 could be used as a potential biomarker for early-stage CRC detection. This evidence concerns the gene CEACAM5 and colorectal carcinoma.